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Mutations in the ras genes are key events in the
process of carcinogenesis; in particular, point muta-
tions in codon 61 of exon 2 of the N-ras gene occur
frequently in cutaneous melanoma. To investigate
whether these mutations occur in early or late tumor
progression phases, we searched for point mutations
in the N- and K-ras genes in 69 primary cutaneous
melanoma, 35 metastases, and seven nevocellular
nevi in association with cutaneous melanoma.
Lesions were microdissected in order to procure
pure tumor samples from the distinctive growth
phases of the cutaneous melanoma; the very sensitive
denaturing gradient gel electrophoresis technique
was used to visualize the mutations, and was
followed by sequencing. Point mutations in the
N-ras gene but not in the K-ras gene were detected
on denaturing gradient gel electrophoresis. Twenty-
three primary (33%) and nine metastatic (26%)
melanomas showed bandshifts for N-ras. In the
majority of cases, mutations occurring in early
growth phases (i.e., the ``intraepidermal'' radial
growth phase), were preserved in later growth phases
(i.e., the invasive radial growth phase, vertical
growth phase, and metastatic phase), which proves
the clonal relationship between the successive growth
phases. In three cases, however, the mutations
differed between the distinctive growth phases within
the same cutaneous melanoma, due to the occur-
rence of an additional mutation (especially in codon
61) in a later tumor progression phase. Our approach
also permitted us to analyze the mutational status of
nevi, associated with cutaneous melanoma. Six out
of seven associated nevi carried the same sequence
(mutated or wild-type) as the primary cutaneous
melanoma, whereas in one case the sequence for
N-ras differed between the primary melanoma and
the associated nevus. In conclusion, this approach
allowed us to demonstrate the clonal relationship
between subsequent growth phases of melanoma and
associated nevi; our results suggest that N-ras exon 1
mutations preferentially occur during early stages of
tumor progression and hence may be involved in
melanoma initiation, whereas those in N-ras exon 2
are found preferentially during later stages and hence
are more probably involved in metastatic spread of
cutaneous melanoma. Key words: carcinogenesis/
DGGE/melanoma/microdissection/Ras. J Invest Dermatol
117:1483±1489, 2001
T
umor progression is the process by which gradual
accumulations of irreversible genetic alterations result
in increasing malignancy, which is re¯ected by
invasion, metastasis, and resistance to therapy. This
process occurs in discrete, sequential steps. Clark et al
(1984) suggested that in cutaneous melanoma (CM) the successive
phases of tumor progression are both clinically and histologically
recognizable. The epidermal radial growth phase (RGP) is the
phase in which the cancer spreads in the epidermis resulting
clinically in an irregular enlargement and color variegation of the
macular pigment cell lesion. The microinvasive RGP is character-
ized by invasion of the dermis by single melanoma cells or small
nests of nonproliferating tumor cells. The vertical growth phase
(VGP) is histologically characterized by the appearance of expansile
nodules in the dermis that may clinically be accompanied by the
appearance of a nodule. The metastatic phase is characterized by
dissemination of tumor cells to lymph nodes or distant organs
(Clark et al, 1984; Elder, 1999). Clinical follow-up of large cohorts
of CM patients has shown that the malignant melanocytes in the
®rst two phases (i.e., the intraepidermal and invasive RGP) do not
have the competence for metastasis (Clark et al, 1989).
The key processes underlying tumor progression are activation of
oncogenes, inactivation of tumor-suppressor genes, and impaired
DNA reparation. Ultraviolet radiation (UV) has been causally
linked to melanoma initiation and progression (van't Veer et al,
1989; Koh et al, 1990). UV is a known melanocyte mitogen and
induces speci®c mutations in cellular genes such as p53 and ras (Van
der Lubbe et al, 1988; Brash et al, 1991). Activated ras genes have
been found in several types of human malignancies, including
melanoma (Bos, 1988). The three members of the ras gene family
are the N-ras gene, located at chromosome 1, the H-ras gene,
located at chromosome 11, and the K-ras gene at chromosome 12
Manuscript received June 27, 2001; revised September 11, 2001;
accepted for publication September 13, 2001.
Reprint requests to: Dr. A. Demunter, Department of Pathology,
Laboratory of Morphology and Molecular Pathology, University Hospital
St. Rafael, Minderbroederstraat 12, B-3000 Leuven, Belgium. Email:
anouk.demunter@uz.kuleuven.ac.be
Abbreviations: CM, cutaneous melanoma; DGGE, denaturing gradient
gel electrophoresis; DOP-PCR, degenerated oligonucleotide primed
polymerase chain reaction; RGP, radial growth phase; VGP, vertical
growth phase.
0022-202X/01/$15.00 ´ Copyright # 2001 by The Society for Investigative Dermatology, Inc.
1483
(Marshall, 1985). Ras proteins share biochemical properties with
G-proteins, known to play a role in the signal transduction pathway
from membrane-bound receptors to adenylate cyclase (Gilman,
1984). All activating mutations in ras genes have in common that
they convert the normal ras proteins into proteins that are capable
of transforming NIH/3T3 cells (Shih et al, 1981). Mutations in
naturally occurring ras oncogenes have been found in codons 11,
12, and 13 of exon 1 and in codons 59 and 61 of exon 2 (Dhar et al,
1982; Reddy et al, 1982; Taparowsky et al, 1983; Bos et al, 1985;
Bar-Eli et al, 1989). Apart from these well-characterized mutations,
we recently described a novel mutation in codon 18 of N-ras exon
1 in a subset of CM with excellent prognosis (Demunter et al,
2001).
In CM, mutations in ras oncogenes have repeatedly been found
although their role in the pathogenesis of CM still remains poorly
understood. An extensive investigation by Albino et al (1989)
revealed mutations in 24% of cultured CM, in contrast to 5%±6%
in noncultured primary and metastatic melanoma. Except for one
mutation in codon 13, all of these were located in codon 61 of N-
ras, which appears to be the favorable region of mutations, due to
the preferential formation of cyclobutane dimers at this site
following UV (Albino et al, 1989). Other studies have shown a
similar N-ras mutation frequency in cultured melanoma cells and a
much lower frequency in primary CM or metastases; K- and H-ras
mutations occur rarely in CM (Platz et al, 1994).
In a previous study, we analyzed survival data in relation to ras
mutations in CM (Demunter et al, 2001) using whole tissue
extracts. Unfortunately, approaches that use extracts from whole
tumors, or cell lines derived from an unknown growth phase, do
not allow study of the chronology of genetic alterations associated
with these discrete stages of tumor progression in CM. Therefore,
in this study, we started from the same material as in our previous
study but used microdissection to obtain DNA samples from
histologically identi®ed tumor progression phases. This technique
allowed us not only to analyze the chronology of Ras mutations
during the progression of CM, but also to demonstrate the clonal
relationship between subsequent growth phases.
MATERIALS AND METHODS
Materials
Cell lines Two cell lines [NCI-H23 (CRL-5800) and HCT-116 (CCL-
247)] with mutations in K-ras exon 1 were obtained from ATCC. N-ras
transfectants 11A15 and 7D8 and melanoma cell line Mel-634 were
kindly provided by C. Aarnoudse (Department of Clinical Oncology,
University Hospital, Leiden, The Netherlands) (Schrier et al, 1991).
MOLT-4 cell line was provided by J. Van Pelt (Laboratory of
Hepatology, University Hospitals Leuven, Belgium) (Verlaan de Vries et
al, 1986).
Patient material This study is based on 69 primary CM and 35
metastases. From 22 patients, both the primary CM and the metastasis
were available for analysis. Seven CM were associated with a contiguous
nevus, including one congenital nevus, one lentigo simplex, two
compound nevocellular nevi, and three sporadic dysplastic nevocellular
nevi. In order to overcome problems related to ®xation artifacts, both
frozen and paraf®n-embedded tissue sections from the same lesions were
used. At ®rst, DNA extractions from whole tissue sections were used to
screen the cases for point mutations. When the denaturing gradient gel
electrophoresis (DGGE) gel, capable of detecting a single point mutation,
indicated the presence of a mutation in the form of an abnormal
migration pattern, the distinctive growth phases of the CM were further
microdissected to evaluate the mutation status of the different tumor
progression phases. In addition, microdissection was performed on several
cases (nevi, primary CM, and metastases) with a wild-type banding
pattern on DGGE in order to con®rm the sensitivity of the technique,
and to exclude the occurrence of false-positive results due to the
polymerase chain reactions (PCRs). As controls, cell lines harboring
well-de®ned Ras mutations were used.
Methods
Microdissection Microdissection was performed on 5 mm thick buffered
formalin-®xed, paraf®n-embedded tissue sections as well as on frozen
sections in cases showing well recognizable, distinctive tumor progression
phases (Fig 1). After staining with hematoxylin and eosin and
Figure 1. Microdissection of the distinctive
growth phases of MM. Frozen section of a
SSMM Clark level IV showing the various
growth phases, i.e. ``pure'' RGP (1), the
``invasive'' RGP (2) and the VGP (3) before (A)
and after (B) microdissection
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con®rmation of the presence of two or more growth phases, both frozen
and paraf®n-embedded consecutive tissue sections were digested by
incubation at 40°C for 3 h in collagenase H (Boehringer Mannheim,
Brussels, Belgium). Different phases of the pigment cell lesions (nevus,
``intraepidermal'' RGP, microinvasive RGP, VGP, and metastatic phase)
were carefully microdissected with a sterile needle under an inverted
microscope (Leica DM IL) using a 10 or 203 objective. In 12 CM,
more than one clone per growth phase was selected. The slides were
placed in a Petriplate and covered with sterile water. Dissection was
joystick-controlled. A total of 20±100 cells were collected from a single
growth phase using serial tissue sections in each case. The cells were
aspirated with another sterile glass needle, transferred to an Eppendorf
tube and resuspended in 5 ml of a solution (260 mM Tris-HCl pH 9.5;
65 mM MgCl2) containing 7 mg per ml proteinase K (Boehringer
Mannheim, Brussels, Belgium). Samples were incubated overnight at
55°C followed by boiling for 1 min to inactivate proteinase K. All
material was used for degenerated oligonucleotide primed PCR (DOP-
PCR).
DNA extractions In 44 cases, genomic DNA was isolated from 10
consecutive frozen whole tissue sections of 20 mm thickness by
proteinase K digestion and phenol±chloroform extraction according to
standard procedures.
DOP-PCR DOP-PCR was performed on a thermocycler (Perkin
Elmer 480) in two separate phases (Table I).
The four ®rst cycles (preampli®cation step) were carried out in a 10 ml
reaction mixture (using ThermoSequenase, Amersham Pharmacia,
Roosendaal, The Netherlands) at low stringency conditions, and were
followed by 30 cycles in a 40 ml reaction volume (using AmpliTaq
polymerase LD, Perkin-Elmer Applied Biosystems, Lennik, Belgium) at
high stringency conditions. Both PCRs contained the UN1-primer (5¢-
CCGACTCGAGNNNNNNATGTGG-3¢, with N = A, C, G, or T)
allowing universal ampli®cation of genomic DNA (Telenius et al, 1992).
Reagents, volumes, and reaction conditions are shown in Table I, and
are slight modi®cations from the originally published paper of
Kuukasjarvi et al (1997). The PCR product was puri®ed (Quiagen
Westburg, Leusden, The Netherlands) before further use.
Speci®c PCR The regions centering on codons 12, 13, and 61 of the K-
and N-ras genes were selectively ampli®ed using PCR. Thermal cycling
was carried out with the GeneAmp PCR system 9600 (Perkin Elmer) in
®nal volumes of 50 ml, containing 10 mM Tris-HCl (pH 8.3), 50 mM
KCl, 2 mM MgCl2, 200 mM each dNTP, 0.2 mM of each primer (for
N-ras exon 1, 5¢-forward-CTGGTG TGAAATGACTGAGT-3¢, 5¢-
reverse-[GC]-GGTGGGATCATATTC ATCTA-3¢; for N-ras exon 2,
5¢-forward-GTTATAGATGGTGAAACCTG, 5¢-reverse-[GC]-ATAC-
ACAGAGGAAGCCTTCG; for K-ras exon 1, 5¢-forward- CCT-
GCTGAAAATGACTGAAT-3¢, 5¢-reverse-[GC]-TGTTGGATCAT
ATTCGTCCA-3¢; for K-ras exon 2, 5¢-forward-GTAATTGAT-
GGAGAAACCTG-3¢; 5¢-reverse-[GC]-ATACACAAAGAAAGCCC-
TCC-3¢) (Neri et al, 1988), 500 ng of DNA, and 2.5 U of Taq
polymerase (AmpliTaq Gold, Perkin Elmer). A 40 bp GC-clamp was
attached to the reverse primer ([GC] = GCCCGCCGCGC-
CCCGCGCCCGGCCCGCCGCCCCCGCCCG) and proved to be
suf®cient for the demonstration on DGGE of the cell line mutations in
both exons of K- and N-ras. The ampli®cation protocol (K-ras and N-
ras exon 1) consisted of 40 cycles with denaturation at 94°C, annealing
at 50°C, and extension at 72°C for 1 min. An initial denaturation step of
94°C for 10 min and a ®nal incubation at 72°C for 2 min were
included. A touchdown PCR was used for K- and N-ras exon 2, to
eliminate nonspeci®c product. After the initial denaturation at 94°C for
10 min, a two-cycle protocol was used with denaturation for 30 s
followed by an annealing at 58°C for 30 s. The next two cycles had an
annealing at 57°C and so on. After 14 cycles (2 3 58°C, 2 3 57°C,
2 3 56°C, 2 3 55°C, 2 3 54°C, 2 3 53°C, 2 3 52°C) another 30
cycles were added with a denaturation at 94°C for 30 s, annealing at
50°C for 45 s, and an extension at 72°C for 60 s. A ®nal incubation at
72°C for 2 min was also included.
DGGE To test the DGGE conditions determined by this approach,
control mutations were analyzed (NCI-H23, HCT-116 from the ATCC
and some melanoma cell lines kindly provided by C. Aarnoudse,
Department of Clinical Oncology, Leiden, The Netherlands). A 12%
polyacrylamide gel containing a 20%±50% gradient of urea and
formamide was suf®cient to detect all of the cell line mutations. To
demonstrate the sensitivity of the DGGE assay, the mutant PCR product
was mixed with the corresponding wild-type PCR product, heated, and
allowed to re-anneal to generate heteroduplexes, i.e., hybrids formed
between mutant and wild-type DNA strands (Fig 2A). DNA from
MOLT-4 cell line (heterozygous for mutation in N-ras codon 12
position 1) was serially diluted with normal human spleen and revealed a
detection sensitivity of 2.5% mutant DNA in the wild-type sample
(Fig 2B).
Forty microliters of PCR product was dried out and loaded on the
gels to run at 170 V for 4 h in 1 3 TAE buffer kept at a constant
temperature of 60°C. After electrophoresis, the gel was stained with
ethidium bromide and photographed by UV transillumination. The
bands were excised from the gel and puri®ed with QIAEX II (Quiagen,
Westburg). DNA sequencing was done to con®rm and identify the point
mutations.
RESULTS
DNA from 111 cases (69 CM, 35 metastases, and seven nevi) was
subjected to selective ampli®cation of the K- and N-ras sequences
Table I. The protocol of Dop-PC1Ra
Reagent Volume Reaction
Preampli®cation step
10 3 high salt bufferb 1 ml Denaturation for 1 min at 94°C
2 mM dNTP 1 ml Annealing for 1 min at 94°C
10 mM UNI-primer 1 ml 3 min ramp from 25°C to 74°C
ThermoSequenase (32 U per ml) (diluted in dilution buffer 1 ml Extension for 2 min at 74°C
delivered with the enzyme 1:2) 4 cycles in total
Digest (Sample 5 ml) 5 ml
H2O 1 ml
ÐÐ
10 ml
Second ampli®cation step add:
10 3 low salt bufferc 5 ml Denaturation for 1 min at 94°C
2 mM dNTP 4 ml Annealing for 1 min at 56°C
100 mM UNI-primer 0.6 ml Extension for 2 min at 72°C
MgCl2 (25 mM) 5 ml 30 cycles in total
H2O 24.9 ml
Taq-Polymerase LD (5 U per ml) 0.5 ml
ÐÐ
50 ml
aProtocol modi®ed from this described by KuukasjaÈrvi et al (1997).
b10 3 high salt buffer = 260 mM Tris-HCl (pH 9.5); 65 mM MgCl2.
c10 3 low salt buffer = 10 mM Tris-HCI (pH 8.3); 50 mM KCI.
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using the PCR/DGGE approach. Screening of DNA extracted
from whole tissue sections revealed wild-type sequences on DGGE
in 74 out of these 111 cases (46 CM, 26 metastases, and two nevi).
In the remaining 37 cases, point mutations in the N-ras gene but
not in the K-ras gene were detected on DGGE (Table II, Fig 3).
To con®rm the ®ndings on the whole tissue extract, mutation
analysis in microdissected growth phases of 28 wild-type cases (21
primary CM and seven metastases) was performed (Table III).
Twenty-three primary CM (33%) and nine (26%) metastatic
melanomas showed bandshifts for N-ras. Of these cases, six CM and
two metastases showed mutations in both N-ras exon 1 and 2.
Fifteen CM and three metastatic melanoma showed only N-ras
exon 1 mutations, whereas N-ras exon 2 bandshifts were found in
two primary CM and four metastatic melanoma (Table II). To
con®rm our results and to exclude false negative results due to
®xation and paraf®n-embedding, or due to too small amounts of
DNA after microdissection, the DNA of six CM was analyzed both
after extraction from whole tissue sections and from microdissected
cells, and both approaches were applied to frozen and formalin-
®xed, paraf®n-embedded tissue. Identical point mutations were
obtained using these different techniques. In the 12 cases in which
more than one clone from the RGP or VGP was selected, identical
results were obtained for the different clones.
The N-ras exon 1 mutations consisted of codon 12 mutations in
which GGT (glycine) was substituted for GAT (asparagine) and
codon 18 mutations in which GCA (alanine) was mutated to ACA
(threonine) (Demunter et al, 2001). The cases with this codon 18
Figure 2. Sensitivity of the DGGE mutation detection assay. (A)
To demonstrate the sensitivity of the DGGE, a mutant sample (lane 2)
(codon 18 mutation) was mixed with a wild type sample (lane 3) to
generate heteroduplexes (lane 1). Mutations were clearly resolved by
showing a band pattern deviant from that of the wild type. (B) DNA
from MOLT-4 cell line (heterozygous for mutation in N-RAS codon 12
position 1) was serially diluted with normal human spleen and revealed a
detection sensitivity of 2.5% mutant DNA in wild type DNA. Lane 1 to
9 represents the dilution of the MOLT-4 cell line (100%, 80%, 60%,
40%, 20%, 10%, 5%, 2.5%, and 0% in lane 9). Lane 10 shows a wild
type pattern of a wild type sample.
Table II. Tumor progression in CM: mutation status of the different growth phases of pigment cell lesions
NR HIST. COMM.ACQ.NCNb CONG.NCNb DYSPL.NCNb RGPb IRGPb VGPb METAb
Cases with different mutation status in the various growth phases
1 ALM IV WTc WTc Q
2 NM IV WTc 12 12
O
3 ALM V WTc WTc Q
Cases with identical mutation status in the various growth phases
4 SSM I 12 12
5 SSM II 18 18
6 SSM III 18
O
18
O
7 SSM III 18 18
8 SSM III 18 18
9 SSM III 12 12 12 12
10 SSM III 18 18
11 SSM IV 18
Q
18
Q
18
Q
12 SSM IV 18 18
13 SSM IV 18 18
14 SSM IV 18
?
18
?
15 SSM IV 12 12 12
16 SSM IV O O
17 SSM IV 12
Q
O
12
Q
O
12
Q
O
18 SSM IV 12
?
12
?
12
?
19 ALM IV 12 12 12
20 ALM IV O O O
21 ALM IV 12 12
22 ALM IV 12
Q
12
Q
23 ALM IV 18 18
24 NM IV Q Q
25 SSM V 12 12
aHistologic type of the CM: acrolentiginous CM (ALM); super®cial spreading CM (SSM) and nodular CM (NM).
bDifferent growth phases are shown, i.e., radial GP (RGP); invasive RGP (iRGP); vertical GP (VGIP) and associated nevocellular nevi (ncn) [common acquired
(comm.acq), congenital (cong.) and dysplastic (dyspi.) ncn] or metastases (META).
cGrowth phase was present and microdissected but revealed a wild-type (WT) sequence for both N-ras exon 1 and 2, 12 Codon 12 mutations were in all cases a
transition from GGT (glycine) to GAT (asparagine), 18 Codon 18 mutations were in all cases a transition from GCA (alanine) to ACA (threonine), Three different
mutations were observed on our DGGE gel in codon 61, which resulted in substitutions of glutamine by arginine (CGA) (Q), lysine (AAA) (O) and one that could not be
identi®ed by sequencing (?).
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mutation are the same cases as previously reported in a separate
paper revealing the functional signi®cance of this mutation
(Demunter et al, 2001). No codon 13 mutations were seen. The
normal amino acid at codon 61 of the N-ras gene is glutamine
(CAA). Three different mutations in this codon were observed on
our DGGE gel, which resulted in substitutions of glutamine by
arginine (CGA), lysine (AAA), and one that could not be identi®ed
by sequencing.
Following microdissection of the distinctive growth phases, 22
primary CM showed identical point mutations in N-ras in
subsequent phases of tumor progression, i.e., in an associated
nevus and the ``intraepidermal'' RGP (cases 4, 9, 11, and 18;
Table II), in the ``pure'' and ``microinvasive'' RGP (cases 5 and
12; Table II), in the RGP and VGP (17 cases; Table II), and in
the VGP and metastasis (cases 9, 15, 17, 19, 20, and 24; Table II).
Moreover, in seven cases, more than two subsequent growth
phases could be microdissected (cases 11 and 18 with a nevus,
RGP, and VGP; cases 15, 17, 19, and 20 with an RGP, VGP, and
metastasis; and case 9 with a nevus, RGP, VGP, and metastasis),
and in all these cases identical point mutations were found
throughout tumor progression. In three primary CM, however,
the DGGE results varied between the various tumor progression
stages, due to the emergence of mutations in later growth phases.
Cases 1 and 3 had wild-type sequences in the RGP and VGP of
their primary CM, but revealed a codon 61 mutation in their
metastasis. One nodular Clark IV CM (case 2; Table II) showed a
codon 12 mutation in the VGP, and an additional codon 61
mutation emerged in its metastasis.
Anatomical site and mutation status were compared in the 69
primary CM. In the group of primary CM with wild-type
sequences, 46% of the CM were from sun-exposed areas; 28% were
situated at covered body areas; and 12% of unknown origin. The
group primary CM with mutations showed similar data; 48% were
from sun-exposed areas; 30% from covered body sites; and in 5%
the site of origin was not known.
DISCUSSION
In this study, we used microdissection of paraf®n-embedded and
frozen sections in combination with a very sensitive PCR
technique and DGGE gels to detect point mutations in the K-
and N-ras exon 1 and 2 regions in 69 primary CM, 35 metastases,
and seven nevi. This technique proved to be very reliable, as
described by others (Bernsen et al, 1998), as identical results were
obtained with DNA extracted from frozen as well as from paraf®n-
embedded tissue and with DNA obtained from whole tissue
samples as well as from single cells, microdissected from the same
sample.
Using this same detection system, we recently discovered a new
mutation in codon 18 of N-ras exon 1 in primary CM associated
with an excellent prognosis (Demunter et al, 2001). Apart from this
novel mutation, 32 out of 104 cases (primary CM and metastases;
31%) revealed one or more mutations in the N-ras gene with
DGGE and sequencing. This is in close agreement with the Ras
mutation rate of 36% detected by Ball et al (1994) using dot blot
hybridization on 100 primary and metastatic melanoma. No K- or
H-ras mutations were detected in our series. Our ®ndings con®rm
that ras mutations preferentially affect the N-ras (Albino et al, 1989;
Platz et al, 1994).
Of the 32 mutated melanomas in our series, eight cases had
mutations in both N-ras exon 1 (codons 12 and 18) and N-ras exon
2 (codon 61) and all other cases showed mutations in either exon 1
or 2 of the N-ras gene. In accordance with previous data no codon
13 mutations were found in our study (Van der Lubbe et al, 1988).
All codon 12 mutations in our samples consisted of a transition
from glycine to asparagine. The majority of the codon 61 mutations
were substitutions from the normal amino acid into either a lysine
or arginine, substitutions known to convert the normal p21 protein
into one with transforming potential (Barbacid, 1987; Bos, 1988).
In contrast to previous studies, no correlation was found between
the mutation status of the CM and the anatomical site (i.e., sun-
Table III. Tumor progression in CM: wild-type samples
Cases that were microdissecteda
Histology
Total number
of cases N° Nevi RGP iRGP VGP META
Cases where DNA was
extracted from whole tissue
CM Clark II 8 3 3 3 5
CM Clark Ill 10 3 3 1 3 1 7
CM Clark IV 22 13 2 8 1 13 6 9
CM Clark V 6 2 2 2 4
Metastasis 26 7 7 19
Total 74 28 2 44
aDifferent growth phases of the primary CM were dissected, i.e., the radial growth phase (RGP), the invasive radial growth phase (iRGP), the vertical growth phase
(VGP), and the associated metastases (META) or nevi (one lentigo benigna, one compound and one dysplastic nevus).
Figure 3. N-ras gene point mutations observed on a DGGE gel.
A 20-50% DGGE gel showing the migration pattern for 9 samples in N-
ras exon 2 (lanes 1 to 9) and 2 samples with aberrations in N-ras exon 1
(lane 10 and 11). Case 1 to 4 showing a transversion from CAA
(glutamine) to CTA (leucine) in codon 61 of N-ras exon 2. Lanes 5 and
8 exhibit a change from CAA (glutamine) to AAA (lysine) in codon 61
of N-ras exon 2. Lanes 6, 7 and 9 contain wild type samples. Lanes 10
and 11 show mutations in codon 12 of N-ras exon 1 (GGT (glycine) to
GAT (asparagine) transition).
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exposed or covered areas of the body) (Van der Lubbe et al, 1988;
Jiveskog et al, 1998).
It has been questioned whether mutations in ras genes are an
early or a late event in the development of CM. A few reports
describe ras mutations in primary CM associated with sun exposure
(Van Elsas et al, 1995; Jiveskog et al, 1998), suggesting that ras
mutations are involved in CM initiation. Other studies have
concluded that most of the activating ras mutations occur during
progression in CM, and that ras mutations are not required for CM
initiation (Albino et al, 1989). Our study is the ®rst to locate ras
mutations within distinctive tumor progression phases. In our
series, 23 of the microdissected primary CM displayed an RGP, and
21 of the neoplastic cells from this phase revealed N-ras mutations
(Table III). The presence of N-ras mutations in the earliest stage of
tumor progression in CM, i.e., the pure RGP, lends support to the
hypothesis that mutations in ras contribute to the initiation of CM.
Although the RGP does precede the VGP in CM, one can never
exclude the possibility that successive clones may outgrow the
original clones within a CM and that in some cases cells from the
VGP may repopulate the RGP. It may therefore be dif®cult to be
certain that N-ras mutations arose at a particular stage of the CM.
Different clones per growth phase, however, were picked in 12
CM of our series and revealed identical results for each growth
phase.
Following microdissection of 25 CM, the majority showed
identical point mutations between the different growth phases of
the primary CM, as well as between the primary CM and the
subsequent metastasis (Table III). In cases 5 and 12 (Table II),
DNA could be isolated from both the pure and the invasive RGP.
The latter stage of tumor progression is characterized by invasion of
the dermis by single CM cells or by small clusters of nonproliferating
cells and should be differentiated from the expansile VGP, as tumor
cells in the invasive RGP are considered not to have metastasizing
potential despite their apparent invasiveness; patients with CM in
this stage indeed carry an excellent prognosis (Clark et al, 1989). The
tumor cells in the invasive RGP are considered to display the same
biologic characteristics (Kath et al, 1989) and the same phenotype as
those in the ``intraepidermal'' RGP (Guerry et al, 1993). Our results
show identical mutations [alanine (GCA) to threonine (ACA)] in
codon 18 of N-ras exon 1 in both the pure and invasive RGP, and
thus suggest that, in addition to the phenotype, also the genotype is
shared by these two early growth phases.
In six cases (case 9, 15, 17, 19, 20, and 24), the mutations found
in the metastasis were identical to those occurring in the VGP.
Previous studies have shown that the VGP and metastatic phase
share many features, including chromosomal abnormalities and
phenotype (Albelda et al, 1990). Our data prove the clonal
derivation of the metastasis from the VGP and thus con®rm
previous cell biologic data that CM cells in the VGP have
metastatic potential.
In ®ve cases (case 9, 15, 17, 19, and 20) we were able to isolate
neoplastic cells from the RGP, VGP, and the metastasis, and in
these ®ve cases an identical set of N-ras mutations was found
throughout the successive phases of tumor progression. These data
prove the clonal relationship between the successive growth phases
and con®rm the data of Wiltshire et al (1995) who used
microdissection and comparative genomic hybridization to illus-
trate the clonal relationship between successive growth phases in
three CM. Our results also con®rm the data of Nakayama et al
(2001) who demonstrated genetic clonality between primary CM
and subsequent in-transit metastases in 25 patients, based upon the
analysis of loss of heterozygosity.
In three CM, an additional mutation, not noted in the primary
CM, emerged in a later tumor progression phase. Two primary
CM (cases 1 and 3, Table II) with wild-type ras genes showed a
codon 61 mutation in their metastasis; one nodular CM (case 2,
Table II), with a codon 12 mutation in the VGP and metastasis,
presented an additional codon 61 mutation in the metastasis.
Although it cannot be completely ruled out that these codon 61
mutations were already present in a small population of tumor cells
in an earlier tumor progression phase, the sensitivity of our
technique renders this unlikely, and suggests that during tumor
progression new mutations have been acquired by neoplastic cells.
These ®ndings are in agreement with recent data from Shellman et
al (2000) who suggested an important role for activated ras in the
progression of CM, and lend support to the model of Clark et al
(1984) in which CM is supposed to progress in a stepwise manner
along distinctive growth phases. This stepwise tumor progression
not only involves activation of oncogenes, but also inactivation or
loss of tumor-suppressor genes. In a recent loss of heterozygosity
study comparing primary CM and matched in-transit metastases
using eight microsatellite DNA markers on six chromosomes, half
of the patients were found to demonstrate an additional loss of
heterozygosity in an in-transit metastasis (Nakayama et al, 2001).
Taken together, our data show a high incidence of N-ras exon 1
mutations in primary CM; in particular, codon 18 mutations were
found to be related with the early growth phases of CM. In
contrast, mutations in codon 61 were more frequently observed in
metastases than in primary CM. These ®ndings may suggest a role
for N-ras exon 2 mutations in later stages of melanoma progression
and a role for N-ras exon 1 mutations in early CM development.
Our approach also permitted us to analyze the mutational status
of nevi associated with CM. The exact place of common and
dysplastic nevi within the scheme of tumor progression of CM is
still debated, and few studies have searched for ras mutations in
nevi. Albino et al found no mutations in common acquired and
dysplastic nevi (Albino et al, 1989). These cases were not associated
with primary CM, however, and do not permit investigation of the
clonal relationship between the two lesions. Carr and Mackie
(1994) investigated congenital nevi and dysplastic nevi: whereas no
mutations were found in dysplastic nevi, a high frequency of N-ras
codon 61 mutations was found in the congenital nevi. In our study,
six out of seven nevi carried the same sequence (mutated or wild-
type) as the contiguous primary CM. Only in case 2, a nodular CM
with a codon 12 mutation in its VGP, did the associated nevus
show a wild-type genotype. Three nevi, associated with super®cial
spreading melanoma (SSM), showed the histologic and cytologic
features of dysplastic nevi. Two of the dysplastic nevi (case 4 and
11, Table II) showed the same N-ras mutation as the adjacent CM,
whereas the third dysplastic nevus (Table III) and the adjacent CM
were free of mutations. One congenital nevus was included in the
study (case 18, Table II) and revealed the same set of mutations as
the contiguous primary CM. Although the number of cases studied
is still small, the ®nding of N-ras mutations in CM and adjacent
congenital or dysplastic nevi in some of our cases is in line with a
previous study (Lee et al, 1997) suggesting that dysplastic nevi and
CM share their cellular response to some mutagenic agents (e.g.,
UV light). In addition, the ®nding of identical mutated sequences
in nevi and contiguous CM suggests a clonal relationship between
the two types of lesions and the possibility that the nevus served as
precursor of the CM.
In conclusion, we have demonstrated that N-ras mutations,
particularly in exon 1, may occur in the earliest phases of tumor
progression of CM and in nevi associated with CM. Mutations, if
present, are mostly preserved throughout tumor progression, which
proves the clonal relationship between the different growth phases
of CM. Additional mutations, especially those in codon 61, may
occur during tumor progression and may play one of the roles in
the development of metastasis in CM.
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